Jivi

Damoctocog Alfa Pegol, the active ingredient in Jivi, is a recombinant factor VIII product presented as a concentrate for intravenous use. It replaces deficient factor VIII activity, providing prophylaxis and on‑demand treatment for patients with hemophilia A. Its pegylated structure extends circulating half‑life, allowing less frequent infusions compared with standard factor VIII concentrates. Jivi is approved for use across the European Union and is included in many national hemophilia treatment programs. GNH USA supplies Jivi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jivi is used to manage hemophilia A, a congenital factor VIII deficiency, by providing replacement therapy. Hemophilia A (prophylaxis): maintains clotting factor levels to prevent spontaneous bleeding episodes. Hemophilia A (on‑demand treatment): controls acute bleeding episodes when they occur. Surgical procedures in hemophilia A patients: provides hemostasis to reduce peri‑operative bleeding.

The safety profile of Jivi includes both common and rare adverse reactions observed in clinical use.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Headache: transient headache during or after infusion. - Fever: low‑grade temperature elevation. - Nausea: mild gastrointestinal upset. - Arthralgia: joint pain. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Development of factor VIII inhibitors: neutralizing antibodies that reduce efficacy. - Anaphylactic reactions: severe allergic response requiring immediate medical attention. - Thromboembolic events: clot formation in vessels. - Hepatic dysfunction: elevated liver enzymes. - Disseminated intravascular coagulation: widespread clotting and bleeding. - Severe allergic reactions: including angioedema.

When prescribing Jivi, healthcare professionals should observe several precautionary measures to ensure safe use. - Inhibitor monitoring: regularly test for anti‑factor VIII antibodies that may diminish treatment effect. - Bleeding history assessment: evaluate patient’s prior bleeding episodes and current anticoagulant use. - Liver function evaluation: check hepatic enzymes before initiating therapy. - Cardiovascular risk: use cautiously in patients with a history of thrombosis. - Hypersensitivity: avoid in individuals with known allergy to any component of the product. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Jivi may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concurrent use of other factor VIII concentrates: may increase risk of inhibitor development. - Therapeutic anticoagulants (e.g., warfarin, heparin): can reduce clotting efficacy of Jivi. - Immune tolerance induction agents: may interfere with antibody response.

Moderate Interactions (Monitor Closely): - Antifibrinolytics (e.g., tranexamic acid): may enhance hemostatic effect, requiring monitoring for thrombosis. - Certain antibiotics (e.g., aminoglycosides): can affect laboratory clotting assays, necessitating dose adjustments. - Vaccinations: may transiently alter immune response, monitor for inhibitor formation.